[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Tourcoing Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":68},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,44],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100650121","platelets-target-the-circulating-hiv-reservoir-implications-for-immunological-failure-100650121",false,"NCT07745530","Platelets Target the Circulating HIV Reservoir: Implications for Immunological Failure","PLAQUAGE - Platelets Target the Circulating HIV Reservoir: Implications for Immunological Failure","PLAQUAGE","Inclusion Criteria:\n\n* Adult patients living with HIV with an undetectable viral load for more than 2 years\n* Beneficiary of a social security scheme or rightful claimant;\n* Patients able to read and understand the information sheet;\n* Having signed the consent form.\n\nExclusion Criteria:\n\n* being unable to give free and informed consent;\n* pregnant or breastfeeding woman;\n* being under guardianship, curatorship, or a protection mandate;","ALL","18 Years",{"count":20,"type":21},90,"ESTIMATED","INTERVENTIONAL",[24],"NA","HIV\u002FAIDS is a chronic disease that is difficult to eradicate because the virus persists as proviral DNA integrated into the host cells. Despite antiretroviral therapy, proviral DNA persists in lymphoid and myeloid reservoirs, whether circulating (memory CD4+ T cells) or tissue-based (macrophages). HIV reservoirs are highly heterogeneous, making it difficult to identify a specific biomarker or cell profile for a given reservoir. A distinctive feature of HIV reservoirs may be the selective interaction between reservoir cells and platelets. The presence of HIV in platelets could impact disease progression, particularly by triggering the reversal of HIV latency and leading to residual viral production. The frequency of platelets containing circulating virus in the blood is approximately 0.1% of the total platelet volume. Although seemingly negligible, this would represent a daily input of 10⁸ platelets harboring the virus. Furthermore, patients whose platelets contain HIV are primarily those with persistent immunological failure, known as \"immunological non-responders\" (InR).\n\nThe regulation of the size (number and frequency) of the HIV reservoir by platelets is not known. However, HIV-containing platelets form more conjugates with CD4+ T cells than HIV-free platelets. While HIV-containing platelets do not productively infect cells, they induce metabolic dysfunction in CD4+ T cells (aerobic glycolysis). Increased aerobic glycolysis is a hallmark of T cell activation and senescence.\n\nThis suggests an interconnection between the presence of the virus in platelets, the size of the reservoir, and immune dysfunction in HIV.",[27],"HIV",[29,30],"hiv","platelet","RECRUITING","2026-07-29",{"date":34,"type":35},"2026-08-04","ACTUAL",{"date":37,"type":35},"2025-04-01",{"date":39,"type":21},"2026-10-01",{"name":41,"class":42},"Tourcoing Hospital","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":67},"100414123","phase-3-rifabutin-versus-rifampicin-for-treatment-of-staphylococcal-pji-treated-with-dair-100414123","NCT04672525","Rifabutin Versus Rifampicin for Treatment of Staphylococcal PJI Treated With DAIR","Rifabutin Versus Rifampicin for Treatment of Staphylococcal Prosthetic Joint Infection Treated With Debridement, Antibiotics and Implant Retention (DAIR Strategy): a Multicenter Randomized, Open-label, Non-inferiority Trial","RIFAMAB","Inclusion Criteria:\n\n1. Hip or knee Prosthetic joint infection treated by debridement, antibiotic therapy initiation and retention of prothesis (DAIR strategy)\n2. Infected with at least one of the following microorganisms:\n\n   1. Staphylococcus aureus\n   2. Coagulase-negative staphylococci\n3. Microorganisms susceptible to rifampicin and at least one other antibiotic suitable for the treatment of PJI (e.g., penicillin, fluoroquinolone, (doxy\u002Fmino)cycline, oxazolidinone, cotrimoxazole, daptomycin, glycopeptide, macrolide, fusidic acid), regardless of sensitivity to methicillin.\n4. Age ≥ 18 years\n5. At least 2 days of appropriate (i.e., covering pathogen(s) identified in the intraoperative samples) empirical agents are needed. Pre-randomization antimicrobial therapy could be: flucloxacillin, oxacillin, vancomycin, daptomycin. β-lactam plus β-lactamase-inhibitors (e.g. ampicillin+sulbactam, piperacillin+tazobactam), cephalosporins (except ceftazidime), carbapenems, teicoplanin, ceftaroline, ceftobiprole.\n6. Signed Inform consent\n7. Patient having the rights to French social insurance\n8. For women of childbearing potential i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile and excluding oestroprogestative-based contraception, any effective contraceptive: vasectomy (for men), intrauterine device copper, feminine sterilization, condom, sexual abstinence is required. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause\n\nExclusion Criteria:\n\n1. Suspicion of reduce absorption of oral treatment due to abdominal disorder Known or suspected malabsorption (imperfect absorption of food material by the small intestine)\n2. Polymicrobial infection due to other than staphylococcus species susceptible to rifampicin\n3. Known or suspected allergy to rifabutin and\u002For rifampicin\n4. Diagnosis of endocarditis associated to PJI\n5. Renal transplant or Chronic kidney disease with an eGFR of less than 30ml\u002Fmin\u002F1.73m²\n6. Other Solid Organ Transplant\n7. Liver cirrhosis, Child-Pugh score C\n8. Any other concomitant infection which required a prolonged course of intravenous antibiotic therapy\n9. Oestroprogestative-based contraception\n10. Oral anticoagulant drugs\n11. Other drug-drug interaction that contraindicated rifampicin or rifabutin\n12. Porphyria\n13. Unable to take oral treatment\n14. Receive empirical postoperative antibiotic treatment by rifampicin or rifabutin prior to randomization\n15. Pregnancy or lactating women\n16. Curator or guardianship or patient placed under judicial protection\n17. Participation in other interventional research during the study",{"count":53,"type":21},436,[55],"PHASE3","Rifampicin, is key in the treatment of staphylococcal PJIs. Rifabutin has a better profile of tolerance than rifampicin regarding the risk of interaction with concomitant medications and liver disorders. The hypothesis is that rifabutin may be an alternative antibiotic option as efficient as rifampicin for the treatment of staphylococcal PJIs, with a better safety profile. The investigator aim to demonstrate the non-inferiority of rifabutin as compared with rifampicin prescribed in combination treatment for PJIs.",[58],"Prosthetic Infection","2022-05-09",{"date":61,"type":35},"2022-05-10",{"date":63,"type":35},"2021-11-08",{"date":65,"type":21},"2027-06",{"name":41,"class":42},30,""]